The Cognite Atlas AI™ Definitive Guide to Industrial Agents Launched as the Premiere AI Manual for Industry
The book is a must-read for transformation leaders looking to accelerate AI innovation and reduce time to value of their digital transformation programs
Cognite, the globally recognized authority in AI for industry, today announcedthe launch ofThe Cognite Atlas AI™Definitive Guide to Industrial Agents, a comprehensive manual for companies looking to accelerate the development and scale of AI solutions and reduce time to value.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904796303/en/
The Cognite Atlas AI™ Definitive Guide to Industrial Agents Launched as the Premiere AI Manual for Industry. (Photo: Business Wire)
The book explores advancements in AI over the past year and expands on industrial AI agents and the latest technological requirements necessary to make AI work for industry. The Cognite Atlas AI™ Definitive Guide to Industrial Agents offers real-world examples, practical advice, and tools digital leaders can use to implement AI agents that can improve decision-making processes and help their organizations achieve higher productivity, safety, and overall operational efficiency.
“According to a recent ARC Advisory Group Digital Transformation, Sustainability, and Technology survey, AI is the most impactful technology we'll see over the next five years,” said Janice Abel, ARC Advisory Group Principal Technology Analyst. “The Cognite Atlas AI™ Definitive Guide to Industrial Agents is a practical place to start for digital leaders looking to make AI work in complex industrial environments.”
“Cognite Atlas AI enables us to use AI to enhance decision-making and improve efficiency, like with an industrial agent fine-tuned to understand unstructured technical documentation and Aker BP’s equipment hierarchy," said Paula Doyle, Chief Digital Officer at Aker BP. "By implementing the Document Parser AI Agent, we are streamlining our equipment management process, saving thousands of hours of data-punching, and refocusing our experts on business problems that really matter to the short- and long-term success of our operation.”
“Data lakes and copilots are just the beginning. Industrial AI demands more than a one-size-fits-all approach,” said Paul Grenet, Chief Revenue Officer at Cognite. “Cognite Atlas AI unlocks the full potential of generative AI for industry with industrial agents that can accelerate efficiencies and generate tens of millions of dollars in business impact. These agents enable a new wave of intelligent, domain-specific applications that revolutionize how industries operate."
The Cognite Atlas AI™ Definitive Guide to Industrial Agents is the third installment of the Cognite Definitive Guide series, which also includes The Definitive Guide to Generative AI for Industryand The Definitive Guide to Industrial DataOps. The series demystifies industrial digitalization and helps make sense of the journey industrial companies must take to evaluate, adopt, and scale AI solutions across their organizations.
The full digital version of the book is available online for free. Physical copies are available by request. Visit Cognite.ai to learn more.
About Cognite
Cognite makes Generative AI work for industry. Leading energy, manufacturing, and power & renewables enterprises choose Cognite to deliver secure, trustworthy, and real-time data to transform their asset-heavy operations to be safer, more sustainable, and more profitable. Cognite provides a user-friendly, secure, and scalable platform that makes it easy for all decision-makers, from the field to remote operations centers, to access and understand complex industrial data, collaborate in real-time, and build a better tomorrow. Visit us at www.cognite.ai and follow us on LinkedIn and Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904796303/en/
Contacts
Michelle Holford
Michelle Holford
Vice President, Global PR, Cognite
Michelle.holford@cognite.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kweichow Moutai’s Brand Culture Activities in Greece Foster Sino-Greek Cultural Cooperation21.12.2024 19:41:00 CET | Press release
On December 9th, the exhibition “Longevity in the Tao of Chrysanthemum: The Artistic World of Qi Baishi,” supported by Kweichow Moutai Group, opened at the Athens University History Museum. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241221429801/en/ Gao Shan(R3), and Petros Tatoulis(R2), took a group photo with other guests at the opening ceremony of the exhibition. (Photo: Business Wire) Featuring the works of Qi Baishi, a renowned Chinese painter, the exhibition highlights the unique charm of traditional Chinese culture for Western audiences, while advancing cultural exchange and mutual understanding between China and Greece. Gao Shan, Chairman of the Labor Union at Kweichow Moutai Distillery (Group) Co., Ltd., remarked on the significance of the event, saying, “Qi Baishi employed distinctive Eastern painting techniques to convey the Chinese perspective of the world. Athens, a city celebrated for its great masters and
Vertex Announces US FDA Approval of ALYFTREK™,a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 21:46:00 CET | Press release
- ALYFTREK™ is approved for patients 6 years and older with at least one responsive mutation, including 31 additional mutations not responsive to other CFTR modulator therapies - - In head-to-head clinical trials, ALYFTREK was non-inferior on ppFEV1 and further decreased sweat chloride compared to TRIKAFTA® - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and t
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants20.12.2024 21:35:00 CET | Press release
- Approximately 300 more people with cystic fibrosis in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 20:32:00 CET | Press release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
Andersen Global udvider sin ekspertise med tilføjelsen af Valora20.12.2024 17:07:00 CET | Pressemeddelelse
Andersen Global fortsætter sin udvidelse af servicetilbud gennem en samarbejdsaftale med Valora, der er en uafhængig virksomhed med speciale i levering af skræddersyede løsninger til både private og institutionelle kunder globalt. Valora har kontorer i Miami og Raleigh og desuden global tilstedeværelse i Den Dominikanske Republik, Storbritannien og Caymanøerne. Valora blev grundlagt i 2011 af partneren Luis de Leon og tilbyder et stort udvalg af tjenester, blandt andet værdiansættelse, performance, regnskab og administration, global enhedsstyring, fondsvirksomhed og andre skræddersyede løsninger. "Et samarbejde med Andersen passer godt til både vores kunder og vores team," siger Luis. "Synergierne mellem for vores servicetilbud vil sætte os i stand til at levere omfattende og integrerede løsninger med stadigt stigende global rækkevidde." Global Chairman og CEO for Andersen Mark L. Vorsatz udtaler: "Valoras team og virksomhedskultur er, sammen med deres fokus på det praktiske, et godt m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom